CARLSBAD, Calif. , Nov. 13, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that company management will participate in the following investor conferences: Jefferies London Healthcare Conference, November 19-21 st ,... Read More

Reported positive interim clinical proof-of-concept results for TYRA-300 in mUC from SURF301 Ph1/2 study IND cleared for Phase 2 study of TYRA-300 in pediatric achondroplasia (BEACH301) Strengthened leadership with appointment of Doug Warner , MD as Chief Medical Officer Cash, cash equivalents, and marketable securities of $360.1 million at Q3 2024 CARLSBAD, Calif. , Nov. 7, 2024 /PRNewswire/ -- Tyra Biosciences, Inc.... Read More

TYRA-300 is the first oral FGFR-3 selective inhibitor to be well-tolerated in clinical studies First child with achondroplasia expected to be dosed in Q1 2025 CARLSBAD, Calif. , Oct. 28, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology,... Read More

Encouraging preliminary anti-tumor activity observed in heavily pre-treated population At ≥ 90 mg QD, 6 out of 11 (54.5%) patients with FGFR3+ mUC achieved a confirmed partial response (PR), with 100% disease control rate and sustained duration of activity Positive safety results across all QD doses, with infrequent FGFR2/FGFR1-associated toxicities Conference call scheduled for October 25th, 2024 , at 8AM EDT CARLSBAD,... Read More

CARLSBAD, Calif. , Oct. 23, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that it will host a conference call and webcast on October 25, 2024 at 8:00 am ET to share interim clinical results of TYRA-300 from the... Read More

TYRA will also present two posters on PK/PD of TYRA-300 and a Trials-in-Progress from SURF301 CARLSBAD, Calif. , Oct. 11, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced the selection of three abstracts for... Read More

CARLSBAD, Calif. , Sept. 11, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced today its participation at the 2024 Cantor Global Healthcare Conference. Todd Harris , CEO of TYRA, will participate in a fireside chat on Tuesday,... Read More

Dr. Warner brings over twenty years of proven clinical development leadership to TYRA having successfully led global development and secured approvals for medicines across oncology and skeletal disease CARLSBAD, Calif. , Sept. 10, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in... Read More

SURF301 Ph1 initial results and ACH IND submission expected in 2H24 Reported preclinical proof-of-concept with TYRA-300 in HCH, demonstrating increases in long bone length and binding against the HCH altered protein - IND cleared for TYRA-430, an FGFR4/3 biased inhibitor for HCC Announced Chief Medical Officer transition plan; search for an external candidate underway with guidance from Science & Technology (S&T) Committee... Read More

In a preclinical HCH model, TYRA-300 demonstrated increases in long bone length and binding against the HCH altered protein TYRA remains on track to submit ACH Investigational New Drug Application (IND) in 2H24 CARLSBAD, Calif. , July 2, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities... Read More

CARLSBAD, Calif. , May 23, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that company management will participate in the following investor conferences: TD Cowen's 5 th Annual Oncology Innovation Summit: Insights for... Read More

TYRA-300 on track in ACH and oncology; SURF301 Ph1 initial results and ACH IND submission expected in 2H24 Cash, cash equivalents, and marketable securities of $382.5 million at Q1 2024 Susan Moran , M.D., M.S.C.E. and S. Michael Rothenberg , M.D., Ph.D. appointed to TYRA Board of Directors CARLSBAD, Calif. , May 9, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on... Read More

CARLSBAD, Calif. , May 7, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced changes to its Board of Directors with the appointments of Susan Moran , M.D., M.S.C.E. and S. Michael Rothenberg , M.D., Ph.D. as independent... Read More

Advanced SURF301 Phase 1 oncology study; Initial Phase 1 results to be reported in 2H 2024 TYRA-300 Phase 2 ACH IND submission on track for 2H 2024 Initiated SURF201 Phase 1 study and dosed first patient with TYRA-200 Strengthened balance sheet with approximately $200 million PIPE in Q1 2024; pro-forma cash, cash equivalents, and marketable securities of approximately $403.5 million CARLSBAD, Calif. , March 19, 2024... Read More

CARLSBAD, Calif. , Feb. 27, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that company management will participate in the following investor conferences: TD Cowen's 44 th Annual Healthcare Conference, March 4-6th :... Read More

CARLSBAD, Calif. , Feb. 7, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that Todd Harris , CEO of TYRA, will present at Oppenheimer's 34 th Annual Healthcare Life Sciences Conference on Tuesday, February 13, 2024 ,... Read More

CARLSBAD, Calif. , Feb. 2, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced today that it has entered into a securities purchase agreement with institutional and accredited investors to sell securities in a private placement... Read More

CARLSBAD, Calif. , Feb. 1, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. ( Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) Designation to TYRA-300, an oral FGFR3 selective... Read More

Initiated SURF201 Phase 1 Study; dosed first patient with TYRA-200 Cleared multiple dose cohorts in SURF301 and continues to dose escalate with TYRA-300 Received FDA feedback on TYRA-300 Phase 2 ACH study: IND submission planned for 2H 2024 CARLSBAD, Calif. , Dec. 22, 2023 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines... Read More

CARLSBAD, Calif. , Nov. 8, 2023 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that management will participate in the 2023 Jefferies London Healthcare Conference, taking place November 14-16 , 2023. Todd Harris , CEO of... Read More

Enrollment and dose escalation ongoing in SURF301 Phase 1/2 oncology Presented additional preclinical data on TYRA-300 in achondroplasia at ASBMR and ASHG First patient to be dosed in TYRA-200 Phase 1 by YE 2023 Strong cash position of $215.7 million as of Q3 2023 CARLSBAD, Calif. , Nov. 7, 2023 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation... Read More

CARLSBAD, Calif. , Sept. 21, 2023 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that TYRA will deliver oral presentations on TYRA-300 for achondroplasia at the American Society for Bone and Mineral Research (ASBMR) and... Read More

CARLSBAD, Calif. , Sept. 12, 2023 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that management will participate at the 2023 Cantor Global Healthcare Conference, taking place September 26-28, 2023 , in New York , NY. Todd... Read More

Orphan Drug Designation granted to TYRA-300 for achondroplasia SURF301 Phase 1/2 oncology study remains on target; enrollment ongoing in Part B TYRA-200 Phase 1 study on track; first patient to be dosed in 2H 2023 Strong cash position of $232.4 million as of Q2 2023 CARLSBAD, Calif. , Aug. 10, 2023 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing... Read More

CARLSBAD, Calif. , Aug. 1, 2023 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its lead precision medicine program, TYRA-300,... Read More

CARLSBAD, Calif. , May 25, 2023 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that management will participate in the following investor conferences: TD Cowen's 4th Annual Oncology Innovation Summit : Todd Harris , CEO of... Read More

SURF301 Phase 1/2 oncology study continues to advance Expanded TYRA-300 clinical development into achondroplasia IND for TYRA-200 cleared with Phase 1 study on track for 2H 2023 Strong cash position of $241.7 million as of Q1 2023 CARLSBAD, Calif. , May 4, 2023 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target... Read More

CARLSBAD, Calif. , March 29, 2023 /PRNewswire/ -- Tyra Biosciences, Inc. ( Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that management will present and participate in the following investor conferences: Cantor's The Future of Oncology Virtual Symposium Todd... Read More

Initiated patient dosing with TYRA-300 in SURF301 oncology study Expanded pipeline beyond oncology into genetically defined conditions with TYRA-300 for achondroplasia Cleared IND for TYRA-200 Phase 1 study; first patient dosed expected in 2H 2023 Well-capitalized with cash and cash equivalents of $251.2 million as of YE 2022 CARLSBAD, Calif. , March 22, 2023 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a... Read More

In preclinical models, TYRA-300 demonstrated significant increases in growth and bone length Phase 2 clinical study for pediatric achondroplasia planned to be initiated in 2024 Conference call and webcast today, March 1 st , at 8:00 am ET CARLSBAD, Calif. , March 1, 2023 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that... Read More

CARLSBAD, Calif. , Feb. 22, 2023 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer, today announced that management will present at the following investor conferences: Cowen 43 rd Annual Healthcare Conference Todd Harris , CEO of TYRA, will participate in a fireside chat... Read More

TYRA-300 is the first oral, FGFR3-selective agent to be evaluated in the clinic Conference call and webcast today, Nov. 29th , at 9:00 am ET CARLSBAD, Calif. , Nov. 29, 2022 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer, today announced the initiation of its SURF301... Read More